Tyrvaya (Varenicline Nasal Spray): Novel Treatment for Dry Eye Disease
Tyrvaya: First FDA-Approved Nasal Spray for Dry Eye Disease
Important Correction: Tyrvaya is a nasal spray containing varenicline (a nicotinic acetylcholine receptor agonist), not a cyclosporine emulsion. It is the first FDA-approved nasal spray for the signs and symptoms of dry eye disease (DED) in adults.
Mechanism of Action
Varenicline activates nicotinic acetylcholine receptors (nAChRs) on the trigeminal nerve endings in the nasal mucosa. This stimulates the nasolacrimal reflex arc, increasing basal tear production via parasympathetic outflow to the lacrimal functional unit (lacrimal gland, goblet cells, meibomian glands). This neural pathway enhances all three layers of the tear film: aqueous, mucin, and lipid.
Clinical Efficacy (ONSET-1 and ONSET-2 Trials)
- Significant improvement in Schirmer's test (tear production) at 4 weeks
- Significant improvement in Eye Dryness Score (EDS) – patient-reported symptom
- Rapid onset: some patients report improvement within days
- Efficacy sustained through 12 weeks
Dosing and Administration
- Dose: One spray (0.03 mg) in each nostril twice daily (~12 hours apart)
- Technique: Prime before first use; insert tip into nostril, aim toward lateral wall, spray while breathing gently; do not sniff hard
- Concomitant Use: No need to wait before using other nasal products (but separate administration if possible)
Common Side Effects (≥5%)
- Sneezing (most common, ~80% – usually transient, decreases with continued use)
- Cough, throat irritation
- Nasal discomfort, epistaxis
- Headache
Advantages Over Traditional Topical Therapies
- Non-ocular route: avoids ocular surface irritation, preservative exposure, and post-instillation blur
- Stimulates natural tear production (all three layers) rather than supplementing
- No immunosuppressive effects (unlike cyclosporine, lifitegrast)
- Convenient nasal delivery
Precautions and Contraindications
- Not studied in patients <18 years, pregnancy, or lactation
- Caution with active nasal/sinus conditions (recent surgery, trauma, ulcer)
- No known drug interactions (minimal systemic absorption)
- Not for acute ocular infections or inflammation
Place in Therapy
- Adjunct or alternative for patients intolerant of topical drops
- Especially useful for aqueous-deficient DED with low Schirmer's test
- Can combine with artificial tears, cyclosporine, lifitegrast, punctal plugs
- Cost/access: prior authorization common; patient support programs available
Tyrvaya represents a novel neurostimulation approach to dry eye disease. Discuss with your eye care provider if it fits your dry eye subtype and treatment goals.
Eye & Vision Disorders - Related Articles
- Driving with Eye Floaters: Safety Guidelines & When to See a Specialist
- Detached Retina: Causes, Symptoms & Treatment - EyeCare Insights
- DIY Eyeglass Tinting: A Cost-Effective Guide
- Visual Field Test and Pupil Dilation: Understanding the Necessity
- Understanding the Abbreviations and Numbers on Your Eyeglass Prescription
- How to Safely Remove Gas Permeable Contact Lenses: A Step-by-Step Guide
- Myopia (Nearsightedness): Definition, Causes, and Correction Options
